Now in its tenth edition, this famous compilation of synonyms for drugs, pesticides and other substances of pharmacological or biochemical interest has become even more international and comprehensive in its scope. Electronic storage of the data has ensured that the book is fully up to date, while the highest degree of cross referencing between entries is guaranteed. The types of names presented are: chemical names, abbreviated chemical names, source names, pharmacological names, pesticide names, names derived from places, plants or persons, research code numbers, and proprietary names (trademarks).

For people working in the fields of biochemistry, pharmacology, pharmaceutics, and toxicology, as well as for medical editors and drug regulatory officers, this work will prove to be an indispensable source of information.

This text provides a practical guide providing step-by-step protocol to design and develop vaccines. Chapters detail protocols for developing novel vaccines against infectious bacteria, viruses, fungi, and parasites for humans and animals. Volume 1: Vaccines for Human Diseases has an introductory section on how vaccines impacted diseases, the immunological mechanism of vaccines, future challenges for vaccinologists, and current trends in vaccinology. The design of human vaccines for viral, bacterial, fungal, parasitic and prion diseases as well as vaccines for drug abuse, allergy, and tumor vaccines are also described in this volume. As a volume in the highly successful Methods in Molecular Biology series, chapters contain introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and practical, Vaccine Design: Methods and Protocols, Volume 1: Vaccines for Human Diseases aims to ensure successful results in the further study of this vital field.

The Nonhuman Primate in Drug Development and Safety Assessment is a valuable reference dedicated to compiling the latest research on nonhuman primate models in nonclinical safety assessment, regulatory toxicity testing and translational science. By covering important topics such as study planning and conduct, inter-species genetic drift, pathophysiology, animal welfare legislation, safety assessment of biologics and small molecules, immunotoxicology and much more, this book provides scientific and technical insights to help you safely and successfully use nonhuman primates in pharmaceutical toxicity testing. A comprehensive yet practical guide, this book is intended for new researchers or practicing toxicologists, toxicologic pathologists and pharmaceutical scientists working with nonhuman primates, as well as graduate students preparing for careers in this area.

Topics in this clinically focused publication devoted to Anticoagulants are: Antithrombin clinical applications and anti-inflammatory effects; Pharmacology and laboratory testing of oral direct thrombin inhibitor Dabigatran; Pharmacology and laboratory testing of the oral Xa inhibitors; Clincial use of the new oral anticoagulants; Pharmacology and safety of new oral anticoagulants-the challenge of bleeding; Emergency reversal of Warfarin anticoagulation - prothrombin complex concentrate compared with plasma; Prothrombin complex concentrate as reversal agent for new oral anticoagulants - lessons from prelinical models; Bleeding with new oral anticoagulants - clinical presentation and management; Treatment of ICH with new oral anticoagulants - a neurologist's view; Management of anticoagulation agents in trauma patients; and Anticoagulation and pediatric patients.

This issue of Heart Failure Clinics examines the pharmacologic approaches to heart failure: optimizing established therapy with a look toward future agents. Topics include the pathophysiologic foundation for the pharmacologic treatment of heart failure, treatment of heart failure with reducted ejection fraction and preserved ejection fraction, treatment of acute heart failure, investigational treatments, and the role of congestive heart failure medications following left ventricular assist device.

This book presents a comprehensive and up to date account of the chemotherapy of parasitic diseases, both human and veterinary. The book starts with an overview of parasitic diseases. The body of the book is divided into two parts: antihelminthic drugs, and antiprotozoal drugs. Both parts start with chapters highlighting the 'biochemical targets' available for chemotherapeutic interference. Individual chapters deal with one chemical class of compounds and describe their origin, structure-activity relationship, mode of action, and methods of synthesis and their status both in clinical and veterinary practice. The book will be useful to a wide spectrum of readers: students embarking on a research career in parasitic chemotherapy, clinicians (and veterinarians) and clinical pharmacologists desiring detailed information about the drugs currently in use, and pharmaceutical technologists wanting to update their knowledge of the methods of manufacture.

Over 25 million people in the U.S. alone have benefited from statins--such drugs as Lipitor, Zocor, Crestor, Pravachol, and other cholesterol-lowering medicines--in preventing stroke, heart attack, and other forms of coronary heart disease. But how did these remarkable, life-saving drugs come into being? In Triumph of the Heart, Dr. Jie Jack Li, a medicinal chemist and expert on drug discovery, tells for the first time the fascinating story of statins. Drawn from discussions with many scientists involved in the discovery and development of these drugs, the book illuminates the human side of science by revealing the role played by persistence, luck, and sudden insight that characterize major discoveries. For scientists in the drug industry, health care professionals, students of medicine, and all those intrigued by the basic human drive to explore and discover, Triumph of the Heart offers a compelling view of one of the most important drug discoveries of our time.

The cyclic purine nucleotides 3',5'-cAMP and 3',5'-cGMP are well-established second messengers. cGMP has recently been covered in a volume of the Handbook of Experimental Pharmacology (volume 191). In addition to 3',5'-cAMP and 3',5'-cGMP, so-called non-canonical cyclic nucleotides exist. These comprise the cyclic pyrimidine nucleotides 3',5'-cCMP and 3',5'-cUMP, the purine nucleotide 3',5'-cIMP, the 2',3'-nucleoside monophosphates and cyclic dinucleotides. In this volume of the Handbook of Pharmacology, word-leading experts in the field summarize our current knowledge on these non-canonical cyclic nucleotides, discuss open questions, future research directions and the pharmacotherapeutic implications. Special emphasis will be given to the emerging roles of 3',5'-cCMP and 3',5'-cUMP as second messengers with regard to generators, effectors, biological functions, inactivation and bacterial toxins. The role of 3',5'-cIMP as potential second messenger will also be critically discussed. Furthermore, we will consider transport of cyclic nucleotides and their potential role as first messengers. The role of the cyclic dinucleotide cGAMP in the immune system will covered, too. Lastly, the book will present important methodological aspects ranging from mass-spectrometric methods for cyclic nucleotide detection to the synthesis of nucleotide analogs as experimental tools and holistic methods for analysis of cyclic nucleotide effects.

This book is a neurochemistry-based companion for Protein Misfolding and Neurodegenerative Diseases: Molecular Targets, an Elsevier title by the same author publishing in December 2014. While the first book focuses on biology and molecular targets, this companion book describes how these targets are regulated by small molecules and disease-modifying compounds. The book begins with a brief introduction to how key proteins become dysfunctional, and each subsequent chapter describes major disease mechanisms in Alzheimer's and other tauopathies. Properties and development status of these molecular targets and disease mechanisms are thoroughly described, as are small molecule effectors of autophagy and dis-aggregating agents.

This second edition provides up-to-date chapters and new chapters focusing on the most recent advances in the field of drug safety evaluation. Divided into seven parts, chapters detail specific aspects related to the experimental design of preclinical studies conducted to support the safety of pediatric and combination drugs, necropsy and histopathology evaluation, mass spectrometry imaging, genetic toxicology protocols including the Pig-a mutation assay, safety pharmacology methods such as automatization of patch-clamp procedures, target safety assessment for investigative toxicology, screening assays for developmental toxicology, and methods to characterize novel translational safety biomarkers like microRNAs. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting to avoid known pitfalls. Authoritative and practical, Drug Safety Evaluation: Methods and Protocols, Second Edition aims to ensure successful results in the further study of this vital field.

This book encompasses major progress and future directions in cytochrome P450 (P450) research. Included are contributions by pioneers in the discovery of P450, with chapters on the molecular and functional properties of P450 and cutting-edge applications knowledge from various fields. P450 research has its roots in metabolism, but the true beginning was in 1962 with the publication by Tsuneo Omura and Ryo Sato in "The Journal of Biological Chemistry "on their discovery of the cytochrome." "Following this groundbreaking study, over the last half-century, research has revealed that many forms of P450 exist in animals, plants and microorganisms. P450 research has expanded into many different fields including medicine, agriculture and biotechnology and has drawn the attention of industries for its bioengineering applications, such as drug development and creation of the blue rose . Also, research on nuclear receptors, which has grown out of research on the regulatory mechanisms of P450 genes, has become an important area in biology, medical science, pharmacology and clinical medicine for example, with recent developments in personalized medicines. This book will draw readers into the important and exciting world of P450 and will encourage young students and scientists in P450 research to continue expanding the field via new approaches."

The Side Effects of Drugs Annual was first published in 1977. It has been continually published since then as a yearly update to the voluminous encyclopedia Meyler's Side Effects of Drugs. Each new Annual continues to provide clinicians and medical investigators with a reliable and critical yearly survey of new data and trends in the area of adverse drug reactions and interactions. An international team of specialists has contributed to the informative Annual by critically interpreting it and by pointing to whatever is misleading.

Personalized Cancer Chemotherapy separately describes and addresses "individualized cancer chemotherapy" (ICC) strategies new and old, to provide readers with new insights into their characteristics and techniques, as well as key debates and future trends in this area. The book devotes chapters to drug sensitivity testing, cancer biomarkers and bioinformatics detection, pharmacogenetics, individualized antimetastatic therapy, drug combinations, assistant chemotherapy, and cost-effectiveness considerations. A major obstacle to controlling cancer growth and metastases in patients is the inappropriate use of anticancer and antimetastatic drugs. Researchers and clinicians are now beginning to focus on ICC also called "personalized cancer chemotherapy" (PCC), to improve therapeutic quality and outcomes by selecting and prescribing the most appropriate and effective drugs. Using genetic, molecular, and bioinformatics data and modern experimental techniques, known tumor genes can be detected more easily than ever before; the average speed of genetic sequencing has increased 15,000 to 50,000 times since the Human Geonme Project was completed. This book will help readers understand the pros and cons of each individualized cancer chemotherapy strategy from different angles so as to make good judgments and predictions of drug responses and clinical outcomes.

Stimulant drugs are widely used in the treatment of ADHD in children and adults. Hundreds of studies over the past 60 years have demonstrated their effectiveness in improving attention span, increasing impulse control, and reducing hyperactivity and restlessness. Despite widespread interest in these compounds, however, their mechanisms of action in the central nervous system have remained poorly understood. Recent advances in the basic and clinical neurosciences now afford the possibility of elucidating these mechanisms. The current volume is the first to bring this expanding knowledge to bear on the central question of why and how stimulants exert their therapeutic effects. The result is a careful, comprehensive, and insightful integration of material by well-known scientists that significantly advances our understanding of stimulant effects and charts a course for future research. Part I presents a comprehensive description of the clinical features of ADHD and the clinical repsonse to stimulants. Part II details the cortical and subcortical neuroanatomy and functional neurophysiology of dopamine and norepinephrine systems with respect to the regulation of attention, arousal, activity, and impulse control on the basis of animal studies. Part III is devoted to clinical research, including recent studies of neuroimaging, genetics, pharmacodynamic and pharmacokinetic properties of stimulants, effects on cognitive functions, neurophysiological effects in humans with and without ADHD and in non-human primates, and comparison of stimulants and non-stimulants in the treatment of ADHD. Part IV is a masterful synthesis that presents alternative models of stimulant drug action and generates key hypotheses for continued research. The volume will be of keen interest to researchers and clinicians in psychiatry, psychology, and neurology, neuroscientists studying stimulants, and those persuing development of new drugs to treat ADHD.

The science of cannabinoids is 50 years old. These past years provided a remarkable and constant number of breakthroughs, showing that the signaling mediated by endocannabinoids and lipid mediators impacts almost every function of the body. Indeed, this represents a special field of research, which allows tackling the complexity of biological functions, and provides potential therapeutic frameworks for a plethora of diseases. The number of exciting discoveries brought up to the scientific community almost on a daily basis highlights the importance of an updated volume on this topic. Particularly, given that potential therapeutic benefits of cannabis and cannabinoids are currently under heavy analysis in many Countries worldwide. Hence, the main objective of this book is to explore not only some of the many functions of endocannabinoids (and lipid mediators) in physiological control of networks at a cellular and molecular level, but also to extend this knowledge for potential use of cannabinoids and/or drugs regulating endocannabinoid levels in vivo as therapeutic target(s) in neurological and neuropsychiatric disorders. In this book new findings and ideas about the endocannabinoid system and its roles as neuronal circuit modulator related to human brain pathologies characterized by alterations in neuroplasticity will be highlighted. Endocannabinoid roles in key systems controlling appetite, pain, learning and memory, as well as sleep and stress responses will be presented. In addition, pathological processes associated with changes in endocannabinoid signaling will be discussed in the context of anxiety, autism, depression and addiction. This book will provide an excellent background to researchers looking for extending their areas of interest, and to newcomers in the field.

The serendipitously discovered link between developmental biology and cancer, touched of an explosion of discoveries on the role of Notch in human malignancies, including every aspect of cancer biology, from control of differentiation, proliferation and apoptosis in transformed cells to angiogenesis, tumor-stroma interaction and anti-cancer immune responses. A number of observations have revealed that Notch even plays a role in the renewal of cancer stem cells and tumor initiating cells, which are thought to be a major cause of resistance to treatment. Targeting Notch in Cancer will provide researchers, oncologists, pharmacologists and students with a detailed understanding of the intricate cross-talk between Notch and other pathways of therapeutic interest so to better design rational drug combinations for specific diseases and disease subsets. Divided into two parts, Part I describes in detail what we know about the genetics, molecular biology, biochemistry and structural biology of Notch, as well as the role of Notch in such processes as angiogenesis and immune surveillance. Without insights gained from these basic studies, rational targeting of Notch in human disease would be impossible. Part II describes the role of Notch and ongoing experimental therapeutic efforts in the most important subtypes of human cancers, organized in a clinically oriented fashion by organs and systems affected

This new volume of Advances in Pharmacology presents pharmacology of the blood brain barrier, focusing on targeting CNS disorders. With a variety of chapters and the best authors in the field, the volume is an essential resource for pharmacologists, immunologists and biochemists alike.

Annual Reports in Medicinal Chemistry provides timely and critical reviews of important topics in medicinal chemistry with an emphasis on emerging topics in the biological sciences that are expected to provide the basis for entirely new future therapies.

Malpractice settlements are large for undetected hydroxychloroquine and chloroquine toxicity which, if untreated, can lead to permanent loss of central vision. Knowledge of the ocular toxicity of these drugs has increased during the past fifty years as their use has expanded. Hydroxychloroquine and Chloroquine Retinopathy is the first single-source book on the subject and is essential for the practicing ophthalmologists, rheumatologists, dermatologists, and internists who prescribe these drugs. It covers clinical topics such as signs and symptoms of toxicity, toxicity screening, ancillary testing, to whom and why the drugs are prescribed and dosing considerations. Additionally, the book addresses practice management considerations, including coding, reimbursement and equipment costs, and the medico-legal responsibilities of the rheumatologist and of the ophthalmologist. Guidelines for the management of hydroxychloroquine and chloroquine vary around the world and differences between the guidelines of the United Kingdom, the United States, and other countries are identified. The book concludes with a collection of case examples illustrating common clinical scenarios and their management. This book is a "must-have" resource for physicians who use these drugs.

For some years, international guidelines on the management of asthma have stressed the importance of early intervention with anti-inflammatory drugs to prevent acute asthma exacerbations and to avert chronic inflammatory damage to the airway. Introduced by a broad survey of the targets for anti-inflammatory drugs, this book proceeds to bring together the most recent research into the mechanisms and clinical benefits of presently available anti-inflammatory treatments including corticosteroids, cromones, and theophylline. For the first time, these drugs are discussed alongside the newly introduced leukotriene modifier drugs, and in the context of frontline research into anti-inflammatory drugs of the future. Leading authorities in their fields evaluate the prospects of novel anti-IgE agents and cytokine antagonists, and examine recent developments in immunosuppressant compounds, protease inhibitors, and selective phosphodiesterase inhibitors. This book is an up-to-date and authoritative survey which will be invaluable to university and pharmaceutical company researchers working on anti-asthma and anti-allergy drugs and to respiratory physicians keeping abreast of developments in their specialty.

This book discusses in detail the structural, evolutionary and functional role of actin and its regulatory proteins in gliding motility in apicomplexan organisms, a unique phenomenon found in actin-myosin cytoskeletal elements. The book also explores the potential of different actin regulators, namely formin, profilin, actin depolymerization factor (ADF), capping proteins (CP and CP ), cyclase-associated protein (CAP) and coronin 13-24 as potential drug targets against malaria. As the chief components of the gliding motor, the actin-regulator proteins are characterized by unique features that make them promising targets for structure-based drug design. Lastly, the book proposes a mathematical model, based on kinetic data mining, to help understand the most vital regulators for actin polymerization dynamics.